SAPS2 > 43
|
1.76 (1.03–3.00)
|
0.038
|
1.93 (1.12–3.34)
|
0.018
|
Chronic pulmonary disease
|
1.68 (0.93–3.04)
|
0.086
|
–
| |
Liver cirrhosis
|
1.89 (0.86–4.17)
|
0.11
|
–
| |
Ab < 3 mo., broad-sp. > 10 d
|
2.21 (1.31–3.71)
|
0.003
|
–
| |
C3G < 3 mo
|
1.64 (0.93–2.90)
|
0.087
|
–
| |
Carbapenem < 3 mo
|
2.59 (1.11–6.06)
|
0.03
|
–
| |
Charlson > 2
|
1.75 (1.04–2.95)
|
0.034
|
–
| |
ESBL colonization at admission
|
1.56 (0.92–2.63)
|
0.10
|
–
| |
Septic shock associated with nosocomial pneumonia
|
2.86 (1.68–4.85)
|
0.0001
|
2.81 (1.66–4.78)
|
<0.0001
|
VAP
|
0.48 (0.24–0.96)
|
0.037
|
0.48 (0.24–0.98)
|
0.04
|
ESBL-PE ICUAP
|
1.57 (0.93–2.64)
|
0.091
|
1.15 (0.65–2.05)
|
0.64
|
ICU-acquired infection before ICUAP
|
0.51 (0.28–0.95)
|
0.033
|
0.52 (0.28–0.97)
|
0.04
|
Others antibiotics between colonization and pneumonia
|
1.49 (0.89–2.52)
|
0.13
|
–
| |
Appropriate empirical antimicrobial therapya
|
1.05 (0.56–1.95)
|
0.88
|
0.66 (0.34–1.27)
|
0.22
|